Trial Profile
Measuring and Predicting Response to Atomoxetine and Methylphenidate
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Jun 2018
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary) ; Methylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- 04 May 2018 Status changed from recruiting to completed.
- 27 Feb 2008 New trial centres added.
- 07 Nov 2005 New trial record.